300. IgG4関連疾患 IgG4-related disease Clinical trials / Disease details
臨床試験数 : 36 / 薬物数 : 49 - (DrugBank : 22) / 標的遺伝子数 : 16 - 標的パスウェイ数 : 98
No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
1 | NCT02705638 (ClinicalTrials.gov) | April 2016 | 7/3/2016 | Treatment of IgG4-Related Disease With Revlimid and Rituximab | Treatment of IgG4-Related Disease With Revlimid and Rituximab: The TIGR2 Trial | Immunoglobulin G Subclass 4 Related Disease;IgG4-related Disease;Autoimmune Pancreatitis;IgG4-related Sclerosing Cholangitis;Retroperitoneal Fibrosis | Drug: Rituximab;Drug: Lenalidomide | Mayo Clinic | Celgene Corporation | Completed | 18 Years | N/A | All | 6 | Phase 1 | United States |
2 | NCT01584388 (ClinicalTrials.gov) | April 2012 | 22/4/2012 | Rituximab in IgG4-RD: A Phase 1-2 Trial | Rituximab (RTX) for IgG4-related Disease (IgG4-RD): a Prospective,Open-label Trial | Retroperitoneal Fibrosis;Autoimmune Pancreatitis;Sialadenitis;Pseudotumor | Drug: Rituximab | Massachusetts General Hospital | Genentech, Inc. | Completed | 18 Years | N/A | All | 30 | Phase 1/Phase 2 | United States |